Stay updated with breaking news from Paul Edick. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Key Insights The considerable ownership by retail investors in Xeris Biopharma Holdings indicates that they...
By Denny Jacob Xeris Biopharma Holdings shares jumped 14%, to $2.56, after the biopharmaceutical company raised part of its outlook for 2023. The stock has...
Xeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on Xeris's focus on innovative drug formulation technology, currently...
Xeris Biopharma Holdings (NASDAQ:XERS) revealed its latest quarterly results that highlighted strong revenue growth driven by its commercial products. “We...
Operator: Hello, everyone and welcome to the Xeris Biopharma Third Quarter 2023 Financial Results Call. My name is Bruno. I'll be operating your call today.